李时珍家方酒品牌怎么样 申请店铺

我要投票 李时珍家方酒在保健酒行业中的票数:11 更新时间:2024-11-22
李时珍家方酒是哪个国家的品牌?     李时珍医药集团位于湖北蕲春,是明代伟大医药学家李时珍的故乡,其丰富而优良的药材资源、独特的自然环境孕育了蕲春古老的中医药文化,为我国重要的药材产地,在当地,素有“路人皆懂医,指草皆为药”之说
李时珍家方酒怎么样

     李时珍医药集团位于湖北蕲春,是明代伟大医药学家李时珍的故乡,其丰富而优良的药材资源、独特的自然环境孕育了蕲春古老的中医药文化,为我国重要的药材产地,在当地,素有“路人皆懂医,指草皆为药”之说。

李时珍医药集团的历史沿于明、清、民国时的李氏酒坊和前店后厂的李时珍药铺(蕲州老街)。1958年4月在蕲州正式挂牌创办李时珍制药厂,生产止咳糖浆等成药共25个品种。1970年8月,开始生产四君子丸、香砂六君丸、六味地黄丸、枸菊地黄丸、归脾丸、黄连素片等。1998年,在李时珍制药厂的基础上整合、并购、组建了李时珍医药集团,使李时珍医药事业得以发扬光大。随着李时珍医药集团有限公司的快速发展,集团目前共有19个中药生产剂型,232个国药准字号产品,4个国家中药保护品种,其中以本草纲目家方酒、麝香祛痛搽剂、香连胶囊等为代表的产品群在全国同类产品中连续多年销量名列前茅。

湖北蕲春本草纲目生物科技园区由李时珍医药集团独家投资建设,园区规划面积2500亩,园内又分为李时珍医药工业园和李时珍本草园等,集GMP药品生产、GAP药材种植、GLP新药科研、GSP医药物流、教学、科普、旅游观光、医疗保健于一体,是华中地区中药现代化生产基地,被称之为“华中药谷”,并被湖北省政府指定为中药实验基地。

集团直接管理全国700多个服务处,营销人员超过9000人,形成“金字塔式”的直营体系。员工在集团有着广泛的发展空间和完善的职业生涯规划,忠诚度和稳定性极高。

自2009年起,集团连续四年上榜中国制药工业百强,2013年荣膺中国制药工业百强第51位。2013年,“本草纲目”品牌被国家工商总局授予驰名保护。

“传时珍医药伟业,谱本草科学新篇”是集团的发展理念,“建百年企业,创世界名牌”是集团的奋斗目标。作为李时珍的衣钵传人,李时珍医药集团弘扬中医药责无旁贷。在传承中医药文化精髓的基础上,用现代化的制药理念和生产技术,对传统中药进行提升改造,用现代化的生产流程和管理方法来生产中药,把传统中药变成现代中药,适应时代发展,满足人民需要。让中医药这一民族瑰宝走向世界,造福人类。


Li Shizhen Pharmaceutical Group, located in Qichun, Hubei Province, is the hometown of Li Shizhen, a great medical scientist in the Ming Dynasty. Its rich and excellent medicinal resources and unique natural environment gave birth to the ancient Chinese medicine culture of Qichun. It is an important origin of medicinal materials in China. In the local area, it is known as "passers-by all know medicine, and the grass is medicine". The history of Li Shizhen Pharmaceutical Group is along the Li's winery in Ming, Qing and the Republic of China and the Li Shizhen pharmacy (Qizhou old street) in QianDian and Houchang. In April 1958, Li Shizhen pharmaceutical factory was officially established in Qizhou, producing 25 kinds of cough syrup and other proprietary drugs. In August 1970, Sijunzi pill, Xiangsha Liujun pill, Liuwei Dihuang pill, Gouju Dihuang pill, Guipi pill and berberine tablet were produced. In 1998, on the basis of Li Shizhen pharmaceutical factory, Li Shizhen Pharmaceutical Group was integrated, merged and established, which made Li Shizhen pharmaceutical enterprise carry forward. With the rapid development of lishizhen Pharmaceutical Group Co., Ltd., the group currently has 19 dosage forms of traditional Chinese medicine production, 232 national pharmaceutical quasi brand products, and 4 national protected varieties of traditional Chinese medicine, among which the product groups represented by compendium of Materia Medica, Shexiang Qutong liniment, Xianglian capsule, etc. have been among the top sales of similar products in the country for many years. Hubei Qichun compendium of Materia Medica Biotechnology Park is exclusively invested and constructed by Li Shizhen Pharmaceutical Group, with a planning area of 2500 mu. The park is also divided into Li Shizhen Pharmaceutical Industrial Park and Li Shizhen materia medica park. It integrates GMP drug production, gap medicine planting, GLP new drug research, GSP medicine logistics, teaching, science popularization, tourism and health care. It is a modern production of traditional Chinese medicine in Central China The base, known as "Chinese Medicine Valley", is designated as the experimental base of traditional Chinese medicine by Hubei provincial government. The group directly manages more than 700 service offices across the country, with more than 9000 marketing personnel, forming a "pyramid style" direct business system. Employees in the group have a wide range of development space and perfect career planning, with high loyalty and stability. Since 2009, the group has been listed in the top 100 of China's pharmaceutical industry for four consecutive years, and won the 51st place in the top 100 of China's pharmaceutical industry in 2013. In 2013, "compendium of Materia Medica" brand was awarded famous protection by the State Administration for Industry and commerce. "Passing on the great achievements of Shizhen medicine, writing a new chapter of science" is the development concept of the group, and "building a century old enterprise, creating a world famous brand" is the goal of the group. As Li Shizhen's successor, Li Shizhen Pharmaceutical Group is responsible for promoting traditional Chinese medicine. On the basis of inheriting the essence of traditional Chinese medicine culture, we should use modern pharmaceutical concept and production technology to upgrade and transform traditional Chinese medicine, use modern production process and management methods to produce traditional Chinese medicine, turn traditional Chinese medicine into modern Chinese medicine, adapt to the development of the times and meet the needs of the people. Let traditional Chinese medicine, a national treasure, go to the world and benefit mankind.

本文链接: https://brand.waitui.com/4b17b5772.html

千城特选小程序码

7×24h 快讯

三六零:前三季度基于“360智脑”能力开发的互联网ToC端产品直接收入占整体营收不超2%

36氪获悉,三六零发布股票交易异常波动公告,公司于2024年10月31日披露了《三六零安全科技股份有限公司2024年第三季度报告》,2024年1-9月归属于母公司所有者的净利润为-5.79亿元。2024年前三季度,基于“360智脑”能力开发的互联网ToC端产品所产生的直接收入在整体营业收入占比不超过2%,对公司业绩不构成重大影响。

9分钟前

小鹏MONA哨兵模式将于明年一季度上线

36氪获悉,小鹏汽车董事长何小鹏在微博发文,小鹏MONA即将于2025年第一季度推出哨兵模式。

9分钟前

爱婴室:股东拟减持不超过1%公司股份

36氪获悉,爱婴室发布公告,股东莫锐强的一致行动人茂强投资、莫锐伟拟通过集中竞价交易方式合计减持公司股份不超过138.54万股(即不超过公司总股本的1%)。

9分钟前

顺丰控股在香港上市据悉计划将价格定在区间中点

顺丰控股在香港上市据悉计划将价格定在区间中点。(财联社)

9分钟前

欧洲央行副行长:降息路径比降息幅度更重要

欧洲央行副行长Luis de Guindos表示,央行显然在降息的道路上,但每次货币政策会议的降息幅度并没有那么重要。他补充说,明年薪资增长将放缓,并且欧洲央行预计通胀将向2%的目标靠拢。“如果我们对明年的通胀预测确实成为现实,那么货币政策路径是明确的,”他周五在马德里的一次会议上说。“我们是降息50个基点还是25个基点的问题就不那么重要了。”(新浪财经)

9分钟前

本页详细列出关于鸿茅药酒的品牌信息,含品牌所属公司介绍,鸿茅药酒所处行业的品牌地位及优势。
咨询